Sugi Predict

Sugi Predict / Compounds / SCHEMBL2895859

SCHEMBL2895859

SCHEMBL2895859

CN(C)C(=O)c1cc2cc[c]cc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 3/20 0.39
▸ HRH4 Q9H3N8 1/20 0.38
▸ RXFP1 Q9HBX9 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ FLT3 P36888 1/20 0.38
▸ AR P10275 2/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37
▸ SLC6A4 P31645 1/20 0.37
▸ SLC6A3 Q01959 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ DAO P14920 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ SRD5A2 P31213 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ HTR2C P28335 1/20 0.36
▸ ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4259995 0.80 HSD17B10 (0.58) MEN1KMT2AFLT3KDM4EMAPT
SCHEMBL1202293 0.79 FLT3 (0.41) FLT3KDM4EMAPTDAOHPGD
SCHEMBL29595772 0.77 FLT3 (0.65) HRH4FLT3KDM4EMAPTDAO
SCHEMBL378260 0.77 FLT3 (0.65) HRH4FLT3KDM4EMAPTDAO
Hydrochloric Acid SCHEMBL35211567 0.76 FLT3 (0.62) HRH4FLT3KDM4EMAPTDAO
SCHEMBL18109249 0.75 ALOX15 (0.60) MEN1KMT2ACYP2D6SLC6A2SLC6A4
SCHEMBL28426144 0.73 HRH4 (0.57) SYKHRH4MAPTDAO
SCHEMBL22152424 0.73 HRH4 (0.55) SYKHRH4RXFP1MEN1KMT2A
SCHEMBL14845694 0.71 PIN1 (0.68) HRH4RXFP1MEN1KMT2AFLT3
SCHEMBL7758397 0.70 FLT3 (0.42) HRH4FLT3KDM4EMAPTDAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140336169-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2014-11-13 — — US claimed
US-8748607-B2 Imidazopyrizine syk inhibitors GILEAD CONNECTICUT, INC. (US) 2014-06-10 — — US claimed
US-20130237520-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-09-12 — — US claimed
US-20130237521-A1 IMIDAZOPYRIZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-09-12 — — US claimed
US-8455493-B2 Imidazopyrazine Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2013-06-04 — — US claimed
US-20100222323-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-09-02 — — US claimed
US-20180086769-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2018-03-29 — — US disclosed
US-9796718-B2 6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine GILEAD CONNECTICUT, INC. (US) 2017-10-24 — — US disclosed
EP-3123864-A1 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2017-02-01 — — EP disclosed
EP-2716157-B1 Imidazopyrazine Syk inhibitors GILEAD CONNECTICUT INC (US) 2016-05-18 — — EP disclosed
US-20160031894-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2016-02-04 — — US disclosed
US-9212191-B2 6-(2,3-dihydro-1H-pyrido-[2,3-b][1,4]oxazin-7-yl)-N-(4-morpholinophenyl)imidazo[1,2-a] pyrazin-8-amine as a spleen tyrosine kinase inhibitor GILEAD CONNECTICUT, INC. (US) 2015-12-15 — — US disclosed
US-9120811-B2 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)imidazo[1,4-A]pyrazin-8-amine for treating leukemia or lymphoma GILEAD CONNECTICUT, INC. (US) 2015-09-01 — — US disclosed
US-20130267496-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-10-10 — — US disclosed
US-20130237520-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-09-12 — — US disclosed
US-20130237521-A1 IMIDAZOPYRIZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-09-12 — — US disclosed
US-8455493-B2 Imidazopyrazine Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2013-06-04 — — US disclosed
US-8450321-B2 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor GILEAD CONNECTICUT, INC. (US) 2013-05-28 — — US disclosed
US-20120220582-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2012-08-30 — — US disclosed
US-20100222323-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-09-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031894-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 SYK 1/4885HRH4 900/4885RXFP1 4493/4885
US-20120220582-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 SYK 1/4885HRH4 900/4885RXFP1 4493/4885
US-20130237520-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 SYK 1/4885HRH4 900/4885RXFP1 4493/4885
US-20180086769-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 SYK 1/4885HRH4 900/4885RXFP1 4493/4885
US-20140336169-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 SYK 1/4885HRH4 900/4885RXFP1 4493/4885
US-20130267496-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 SYK 1/4885HRH4 900/4885RXFP1 4493/4885
US-20100222323-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 SYK 1/4885HRH4 900/4885RXFP1 4493/4885
US-20130237521-A1 IMIDAZOPYRIZINE SYK INHIBITORS SYK, ZAP70, BTK SYK 1/4885HRH4 712/4885RXFP1 4316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.